Indaptus Therapeutics (Indaptus Therapeutics) Debt-to-EBITDA : -0.01 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Indaptus Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Indaptus Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.07 Mil. Indaptus Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-16.72 Mil. Indaptus Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Indaptus Therapeutics's Debt-to-EBITDA or its related term are showing as below:

INDP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.02 Med: -0.01 Max: -0.01
Current: -0.01

During the past 4 years, the highest Debt-to-EBITDA Ratio of Indaptus Therapeutics was -0.01. The lowest was -0.02. And the median was -0.01.

INDP's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs INDP: -0.01

Indaptus Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Indaptus Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Debt-to-EBITDA Chart

Indaptus Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.02

-0.01

Indaptus Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.01	-0.01	-0.02	-0.01	-0.01

Competitive Comparison of Indaptus Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Indaptus Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Debt-to-EBITDA falls into.

Indaptus Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Indaptus Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.102	+	0.073)	/	-16.377
	=	-0.01

Indaptus Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.102	+	0.073)	/	-16.716
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Indaptus Therapeutics (NAS:INDP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Indaptus Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Columbus Circle, 15th Floor, New York, NY, USA, 10019

Website

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

Executives

Glen R. Anderson	10 percent owner	3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman	officer: Chief Medical Officer	C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell	director	4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev	officer: Chief Medical Officer	13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert	director	13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee	director, 10 percent owner	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397